Oncolytic Virus Therapy Development for Breast Cancer
Alfa Cytology provides comprehensive preclinical CRO services dedicated to the development of oncolytic virus (OV) therapies for breast cancer. By harnessing the natural tumor-selective replication and lytic capabilities of oncolytic viruses, we help researchers explore innovative treatment strategies aimed at overcoming resistance and improving therapeutic outcomes in various breast cancer subtypes.
Our Services
Virus Engineering and Optimization
Design and modification of oncolytic viruses, including adenovirus, vaccinia virus, herpes simplex virus, and others, tailored for breast cancer-specific targeting and enhanced antitumor efficacy.
In Vitro Efficacy Evaluation
Assessment of viral infectivity, replication kinetics, oncolysis, and immune activation in breast cancer cell lines and 3D tumor spheroid models.
In Vivo Preclinical Studies
Establishment of breast cancer mouse models for evaluating oncolytic virus biodistribution, tumor regression, immune response, and safety profiling.
Combination Therapy Assessment
Evaluation of OV therapies in combination with chemotherapy, immunotherapy, or radiotherapy in preclinical breast cancer models to explore synergistic effects.
Key Advantages
| Breast Cancer-Specific Viral Strategies | Oncolytic viruses are engineered with tumor-selective promoters and immune modulatory genes specifically optimized for breast cancer treatment applications. |
| Integration with Advanced Models | Both 2D cell-based systems and 3D tumor spheroid platforms, as well as animal models, are applied to ensure comprehensive preclinical assessment. |
| Immune Response Profiling | Preclinical models allow simultaneous evaluation of oncolytic effects and host immune responses, supporting immunotherapy development pipelines. |
| IND-Enabling Preclinical Packages | We deliver well-documented, publication-ready data packages aligned with regulatory standards for IND-enabling studies and early-phase development planning. |
Download our brochure to discover how our preclinical oncolytic virus development services can accelerate your breast cancer research program. For customized service inquiries or technical consultations, please contact us directly.
Therapeutic Development for Breast Cancer
Case Study - In Vivo Efficacy
To evaluate the therapeutic potential of our CD47-targeted oncolytic viruses against breast cancer brain metastases (BCBM), we conducted parallel studies in complementary models: Immunodeficient Model: Human BCBM tumors were established via intracranial injection in mice. One week post-engraftment, animals received OV-αCD47-G1, OV-αCD47-G4, or saline control.
Immunocompetent Model: To validate cross-species applicability, mouse-specific variants (OV-A4-IgG2b, OV-A4-IgG3) engineered with anti-mouse CD47 antibodies were tested against syngeneic brain tumors.
Fig.1 Survival analysis of mice bearing MDA-MB-231 tumors.
Fig.2 Assessment of the survival of C57BL/6 immunocompetent mice bearing E0771 tumors.
Both models demonstrated significant survival extension (Fig. 5 & Fig. 6):
Human-targeted viruses (OV-αCD47-G1/G4) overcame immunosuppression in the xenogeneic setting. Species-matched viruses (OV-A4-IgG2b/IgG3) maintained efficacy in intact immune microenvironments.
